Definium Therapeutics, Inc.
DFTXDefinium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
10dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DFTX Earnings Report
EPS Est: $-0.55 | FQ end 2026-06
How DFTX's past catalysts played out
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
DT120
Major Depressive Disorder
MM-120 (LSD D-Tartrate)
Anxiety Generalized
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
DT120 | Phase 3 | Major Depressive Disorder | - | - |
MM-120 (LSD D-Tartrate) | Phase 2 | Anxiety Generalized | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Definium Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Definium Therapeutics, Inc.'s (DFTX) pipeline across Phase 3, Phase 2. Its lead program is MM120 (LSD D-Tartrate) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Definium Therapeutics, Inc.'s next FDA catalyst?→
Definium Therapeutics, Inc.'s (DFTX) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DFTX biotech catalysts?→
Add DFTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Definium Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.